AI Consensus Investment Thesis
VCEL: Vericel Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Vericel: 1-Year and 5-Year Forecast Outlook and Rating
Vericel (VCEL) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $44.3 for , with -18.89% expected return (-18.89% including net dividends) and a SELL ALL rating.
The 5-year target is $68.1 for , with +24.68% expected return (+24.68% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 54.6, as of 6 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-06.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Vericel Flagship Insight
Cellular Therapy Cash Inflection Confronts Restrictive Valuation Compression In Orthopedic Expansion
Reports show high consensus that completed manufacturing expansion and arthroscopic sports medicine adoption accelerate cash flow generation. However, sharp valuation divergence persists regarding whether surging operational earnings can overcome multiple compression driven by elevated interest rates, commercial payer prior authorization friction, and prospective allogeneic technological obsolescence.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Ray Dalio (Strategist)
Universal Investor (Polymath)
Superintelligence (Anthropologist)
Elon Musk (Visionary)
Machiavelli (Insider)
J.P. Morgan (Titan)
Warren Buffett (Value Purist)
Michael Burry (Vulture)
Sherlock Holmes (Whistleblower)
Ran across these frontier AI models
Google Gemini 3.8 Flash
Anthropic Claude Opus 5
OpenAI GPT-6 Astra
Latest published deep-analysis batch. Audit published forecasts in full transparency
Vericel: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Vericel at the latest market close (6 Nov 2026): $12,468 by Sept 2031 versus $14,376 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Vericel is executing a fundamental operational transition from capital-intensive cleanroom construction to high-margin cash harvesting. The completion and regulatory approval of the Burlington manufacturing facility terminates peak capital expenditure, permitting gross margins to structurally hold above 74% as autologous batch throughput accelerates. Minimally invasive arthroscopic delivery expands the addressable orthopedic surgeon base into high-throughput outpatient centers, while federal burn procurement stabilizes non-dilutive baseline revenues. However, trading at an elevated trailing multiple in a restrictive interest-rate regime leaves the equity highly vulnerable to duration discount compression, requiring sustained operating margin expansion to offset systemic multiple derating.
Key insights
- Fixed overhead absorption at Burlington converts incremental biological revenue into expanding operating cash flow, but high equity compensation dilutes headline cash conversion.
- Arthroscopic delivery accelerates surgeon conversion velocity, yet stringent commercial payer prior authorizations and mandatory step therapies continually extend biopsy-to-implantation cash cycles.
- A debt-free balance sheet and authorized share repurchases provide immediate downside support, but long-term terminal value remains exposed to competing allogeneic cartilage platforms.
Continue reading Vericel analysis with Base subscription
See Base accessVericel: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 54.6, as of 6 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-06.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 40. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $41.7 | +4.15% | -23.65% | -23.65% | Year-end insurance deductible exhaustion accelerates fourth-quarter surgical implants, while initial share repurchase execution supports prices. However, elevated Treasury yields and macroeconomic discount-rate pressure cap broader multiple expansion, keeping net quarterly appreciation moderate. | $38.0 | $44.0 | $750 | |
| $41.6 | -0.12% | -23.84% | -23.84% | Annual deductible resets and insurance re-authorizations induce seasonal procedure slowdowns. Headline operating margins contract amid dual-facility depreciation, while persistent central bank rate discipline dampens speculative sentiment, prompting routine first-quarter valuation consolidation across medtech equities. | $38.7 | $44.5 | $736 | |
| $42.7 | +2.59% | -21.82% | -21.82% | Second-quarter surgical volumes rebound as newly trained sports medicine surgeons increase arthroscopic case frequency. Commercial manufacturing runs at Burlington demonstrate early batch efficiencies, expanding gross margins and generating positive operating cash flow. | $38.0 | $47.6 | $743 | |
| $44.3 | +3.68% | -18.89% | -18.89% | Summer sports injury volume maintains consistent biopsy velocity, while federal burn procurement shipments under the BARDA contract provide non-cyclical revenue baselines. Moderating capital spending supports trailing cash flow, offsetting broader equity market multiple stagnation. | $39.5 | $50.5 | $755 | |
| $46.9 | +5.83% | -14.13% | -14.13% | A potent fourth-quarter procedural rush drives record cartilage implant revenue. Operating leverage becomes clearly visible as Burlington fixed overhead absorbs, prompting sell-side earnings revisions and strong year-end institutional accumulation despite prevailing interest-rate headwinds. | $41.5 | $54.5 | $776 | |
| $46.4 | -0.90% | -15.05% | -15.05% | Routine first-quarter procedural lulls and healthcare deductible resets temporarily soften reported quarterly net income. Active open-market share repurchases provide downside price support, buffering equity valuation as investors evaluate full-year operational guidance. | $39.8 | $56.7 | $787 | |
| $48.7 | +4.83% | -10.84% | -10.84% | Spring surgical conversions accelerate alongside encouraging clinical enrollment progress in the MASCOT ankle trial. Higher batch throughput at Burlington lowers unit production costs, reinforcing gross margins above 75% and driving positive earnings momentum. | $41.0 | $60.7 | $803 | |
| $49.7 | +2.07% | -9.01% | -9.01% | Seasonal elective surgery moderation intersects with commercial payer prior-authorization scrutiny, slightly extending biopsy conversion cycles. Steady burn care cash flows and disciplined commercial expenditure preserve operating margins, sustaining orderly trading within the multi-year band. | $40.2 | $63.7 | $812 | |
| $52.0 | +4.62% | -4.80% | -4.80% | Year-end surgical concentration pushes full-year revenue past guidance milestones as Burlington cleanrooms achieve higher capacity utilization. Sinking capital intensity lifts free cash flow conversion, enabling accretive share retirements that enhance per-share fundamental valuation. | $42.6 | $68.2 | $839 | |
| $52.3 | +0.53% | -4.25% | -4.25% | Predictable post-holiday procedure deceleration and winter scheduling delays prompt modest seasonal profit taking. Unencumbered balance-sheet liquidity and zero funded debt insulate operations completely from broader macroeconomic credit volatility, maintaining price stability. | $40.5 | $70.2 | $851 | |
| $54.7 | +4.59% | +0.15% | +0.15% | Pivotal clinical readout announcements for the ankle cartilage indication expand long-term total addressable market expectations. Second-quarter sports medicine case volumes rebound strongly, while automated processing efficiencies lift trailing operating income to fresh highs. | $42.1 | $74.4 | $872 | |
| $56.1 | +2.67% | +2.71% | +2.71% | Core knee repair growth normalizes toward steady mid-teens compounding, while emerging clinical presentations of alternative allogeneic scaffolds temper long-term terminal valuation multiples. Continued share repurchases and international regulatory progress support steady price consolidation. | $40.8 | $78.2 | $886 | |
| $58.9 | +4.94% | +7.84% | +7.84% | Another robust fourth-quarter procedural performance generates record annual operating cash flow exceeding eighty million dollars. High-margin autologous cellular demand confirms business model durability, overcoming broader macroeconomic deceleration through biological standard-of-care entrenchment. | $42.9 | $82.8 | $910 | |
| $59.1 | +0.36% | +8.20% | +8.20% | Annual surgical schedule resets and transitional operating expenses ahead of supplemental regulatory filings induce minor quarterly margin compression. Substantial cash reserves and absence of debt maturities reassure institutional holders, preventing protracted valuation drawdowns. | $41.6 | $85.3 | $916 | |
| $61.5 | +4.11% | +12.60% | +12.60% | Regulatory progress and commercial preparations for expanded extremity indications re-energize orthopedic surgeon interest. Burlington operates at mature batch economics, generating robust quarterly free cash flow that funds ongoing capital return programs. | $43.2 | $90.3 | $937 | |
| $62.3 | +1.31% | +14.06% | +14.06% | Procedural demand demonstrates steady high-single-digit expansion across established sports medicine networks. Terminal growth expectations stabilize around mature medtech benchmarks, keeping valuation multiples aligned with expanding GAAP earnings power rather than speculative platform expansion. | $42.4 | $94.8 | $947 | |
| $65.0 | +4.24% | +19.00% | +19.00% | Record fourth-quarter procedure density across knee and burn franchises delivers strong year-end earnings. Operating margins sustainably approach the high teens as fixed infrastructure costs distribute across mature volume, driving solid annual equity compounding. | $44.5 | $101 | $970 | |
| $64.7 | -0.47% | +18.45% | +18.45% | Familiar first-quarter procedural resets and routine healthcare policy debates create mild early-year consolidation. The company's unencumbered balance sheet and dependable recurring biopsy orders establish an elevated valuation floor against cyclical market pullbacks. | $42.7 | $103 | $980 | |
| $66.5 | +2.84% | +21.75% | +21.75% | Commercial contributions from expanded indication rollouts and international distribution partnerships supplement core domestic knee revenues. Strong return on invested capital and consistent cash conversion attract long-term value capital, supporting consistent quarter-over-quarter share appreciation. | $44.0 | $109 | $1,000 | |
| $68.1 | +2.41% | +24.68% | +24.68% | The five-year forecast culminates with the enterprise operating as a mature, self-funding regenerative medicine platform. Multiple compression toward realistic peer levels completes, leaving total equity returns driven by durable per-share operational earnings compounding. | $44.1 | $113 | $1,012 |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Vericel Stock Analysis & Scenarios Deep Dive
Vericel: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Market consensus views the company as an expensive specialty biopharma asset trading near eighty-four times trailing earnings in a restrictive monetary environment. Prevailing commentary anchors on post-expansion facility depreciation, quarterly surgical seasonality, and insurer prior-authorization friction. Investors largely assume that elevated interest rates will mechanically cap valuation multiples, treating autologous cell therapy as an artisanal, niche procedure nearing domestic market saturation.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates underlying cash generation, creating mild underpricing on a cash-flow basis despite optical multiple stretch. The market fixates on trailing GAAP earnings depressed by facility buildout costs, missing that capital expenditures collapsed from 27% of revenue to single digits. This capex cliff unleashed forty-nine million dollars in trailing free cash flow. While arthroscopic delivery and fixed-cost absorption expand normalized owner earnings, the analytical challenge remains that elevated risk-free yields will compress terminal multiples, dampening equity gains relative to cash flow.
Repricing Catalyst
What could make the market recognize and close that gap? The decisive catalyst cluster centers on consecutive quarterly earnings releases throughout 2027 confirming gross margins holding above 75% alongside annual free cash flow exceeding sixty million dollars. Accelerating biopsy conversion from MACI Arthro adoption and steady federal NexoBrid deliveries will demonstrate unmistakable operating leverage. This cash inflection will force institutional screening models to look past headline trailing multiples, prompting an upward valuation repricing as share buybacks reduce share float.
Vericel: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Growing Awareness
Sentiment converges around growing operational awareness, but opinions sharply diverge between models expecting aggressive valuation rerating and those anticipating heavy discount-rate multiple compression. This tension dictates whether near-term equity gains mirror operational cash flow acceleration or remain subdued.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop represents a mixed setup. A hawkish monetary regime and elevated Treasury yields impose direct valuation compression on long-duration equities. However, zero debt, over two hundred million dollars in liquidity, and biologically non-discretionary joint preservation demand completely insulate core operations and cash generation from credit tightening and broader economic volatility.
Advisor Disagreement
What do our AI Advisors disagree about most? The core debate centers on whether surging operational cash flows can overpower macro valuation headwinds. Bullish views argue that the post-Burlington capital expenditure collapse and arthroscopic surgeon expansion will unlock operating margins above 20% and fuel substantial buybacks, driving aggressive equity rerating. Conversely, skeptical views contend that paying eighty-four times trailing earnings in a 5% interest rate environment guarantees severe multiple compression, as bespoke autologous manufacturing faces structural margin ceilings and terminal allogeneic competition. Resolving this tension requires tracking whether quarterly GAAP operating margins sustainably exceed 12% through 2027.
Vericel: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Burlington facility manufacturing scale unlock | Operational Efficiency | +32% | +52% | FDA approval and commercial ramp of the Burlington production center eliminate historical cell-culture bottlenecks, tripling batch capacity. Concentrating manufacturing under automated cleanrooms spreads fixed labor and facility overhead across escalating volumes, expanding gross margins toward 76%. This structural leverage converts incremental cartilage repair revenue directly into substantial operating profit and unencumbered free cash flow. |
| MACI Arthro arthroscopic surgeon expansion | Innovation And Product | +28% | +45% | Commercial rollout of MACI Arthro instrumentation eliminates invasive open arthrotomy, expanding the addressable sports medicine orthopedic surgeon base from five thousand to over seven thousand clinicians. Arthroscopic delivery lowers patient recovery friction and accelerates biopsy-to-implant conversions, driving durable 20% annual cartilage repair volume growth and compounding high-margin biologic revenue over the five-year forecast horizon. |
| Autologous biologic monopoly and pricing power | Competitive Positioning | +22% | +28% | Holding the sole FDA-approved autologous cellularized scaffold for knee cartilage repair creates an impenetrable regulatory and clinical barrier. Replicating proprietary patient-specific culturing protocols requires years of clinical trials and substantial capital investment, completely excluding generic competition. This monopolistic positioning secures premium pricing above $60,000 per implant, insulating gross margins and cash generation from inflationary shocks. |
| Post-capex cash allocation and repurchases | Capital Allocation | +18% | +20% | With major Burlington construction concluded, capital expenditure intensity collapsed from 27% of revenue to maintenance levels below 8%. Generating nearly $50 million in trailing free cash flow allows management to deploy its $200 million share repurchase program. Funded entirely by operating liquidity with zero debt, systematic share retirements neutralize compensation dilution and accretively compound earnings per share. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Elevated interest rate valuation multiple compression | Macroeconomic And Macrofinancial | -24% | -4.0% | Trading at an elevated trailing earnings multiple near 84x and 52x EV/EBITDA leaves the stock acutely vulnerable to higher-for-longer discount rates. Benchmark 10-year Treasury yields hovering near 5% systematically compress long-duration equity multiples. Even robust operational earnings execution will see headline stock price appreciation heavily dampened as institutional valuation models derate specialty biopharma multiples toward historical norms. |
| Commercial insurer prior authorization friction | Regulatory | -14% | -16% | Commercial health insurers and Medicare Advantage plans continue enforcing aggressive utilization management, mandating step therapies and extensive conservative treatment documentation before approving costly cell implants. This administrative gatekeeping elongates the sales cycle from biopsy harvest to surgical implantation, increasing cancellation rates and requiring elevated corporate expenditures on reimbursement support personnel to defend procedural conversions. |
| Autologous cellular logistics margin ceiling | Operational Efficiency | -12% | -15% | Personalized autologous therapy requires harvesting living human tissue, specialized cryogenic transport, individual batch culturing, and re-implantation. These bespoke operational logistics impose an irreducible cost floor that automation cannot fully eliminate. Cleanroom labor wage inflation and single-facility processing concentration permanently cap operating margins around 20%, preventing the company from achieving software-like biopharma profit conversion. |
| Burlington facility depreciation accounting drag | Operational Efficiency | -10% | -14% | Capitalizing the state-of-the-art Burlington manufacturing complex more than doubled annual depreciation and amortization charges above $13 million. Maintaining dual facility operations during ongoing validation while cleanroom throughput scales introduces significant fixed overhead. This ongoing non-cash accounting drag compresses reported GAAP operating margins to single digits, discouraging conservative value investors who screen strictly on optical net income. |
Vericel: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 59/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Disruptive off-the-shelf allogeneic cartilage emergence | 22% | -38% | A competing biotechnology developer could publish breakthrough Phase 3 clinical efficacy for an off-the-shelf allogeneic or synthetic chondral scaffold by 2029. Eliminating the invasive primary biopsy surgery and weeks of individualized cleanroom culturing would induce rapid surgeon substitution toward single-stage repairs. This technological disruption would rapidly dismantle the company's autologous moat, forcing steep price concessions and triggering terminal multiple collapse. |
| Burlington manufacturing cleanroom contamination shutdown | 16% | -40% | A severe microbial contamination event or adverse FDA cGMP inspection at the centralized Burlington cell-processing facility could force an immediate commercial suspension. Because autologous cell therapy involves perishable, patient-specific living tissues that cannot be inventoried or rapidly outsourced, an operational shutdown would instantly vaporize quarterly revenues, incur substantial remediation costs, and inflict lasting reputational damage among prescribing orthopedic surgeons. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| MACI ankle talar indication label clearance | 36% | +32% | Successful pivotal readout from the Phase 3 MASCOT clinical study could trigger supplemental FDA approval for talar cartilage defects of the ankle by 2028. Ankle cartilage repair represents an underserved domestic market of over twenty thousand annual procedures with zero approved cellular competitors. Leveraging established sports medicine sales rails would unlock over $1 billion in incremental market opportunity, expanding earnings power by 30%. |
| International regulatory authorization and European commercialization | 30% | +28% | Securing marketing authorization from the UK MHRA followed by European distribution partnerships would establish the company's first commercial presence outside the United States. Utilizing Burlington's export-qualified capacity to serve European sports medicine demand would generate high-margin royalty and transfer revenues without heavy overseas commercial infrastructure outlays. This catalyst remains under 50% probability due to rigorous single-payer cost-effectiveness assessments across European health systems. |
Company Financial AnalysisVericel: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Vericel financials here.
Earnings and financials
Vericel has successfully transitioned from an unprofitable clinical-stage development firm into a commercial business generating positive operating income. For the trailing twelve months ended June 2026, revenue expanded to $306 million while net income reached $24.2 million, driven by strong 23% growth in MACI knee implants and growing burn treatment sales. This performance confirms that customer demand is expanding steadily. However, reported accounting profits experience sharp seasonal fluctuations. First quarters frequently show net losses due to annual insurance deductible resets, while fourth quarters deliver outsized profits as patients complete year-end procedures. The fundamental financial trajectory remains positive as rising case volumes absorb fixed corporate overhead.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 276.3M | USD 16.5M | USD 24.7M |
| 2024 | USD 237.2M | USD 10.4M | USD -5.8M |
| 2023 | USD 197.5M | USD -3.2M | USD 7.8M |
| 2022 | USD 164.4M | USD -16.7M | USD 10.1M |
| 2021 | USD 156.2M | USD -7.5M | USD 21.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Gross profit margins have expanded structurally from under 69% in 2023 to over 74% in 2025, driven by premium product pricing and improved cell-culturing efficiency. Because autologous cell therapy manufacturing costs are largely fixed, processing higher patient volumes through automated Burlington bioreactors allows gross margins to hold near 75%. Below gross profit, GAAP operating margins sit near 6% due to high facility depreciation, commercial sales force investments, and stock-based employee compensation. As specialized sales territories mature and batch throughput expands across the forecast horizon, operating leverage should gradually expand operating profitability toward mid-teens.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11M | 4.0% | 6.0% |
| 2024 | USD 4.5M | 1.9% | 4.4% |
| 2023 | USD -6.5M | -3.3% | -1.6% |
| 2022 | USD -17.1M | -10.4% | -10.2% |
| 2021 | USD -7.9M | -5.0% | -4.8% |
Balance sheet and leverage
Vericel commands a fortress balance sheet characterized by zero funded bank debt and approximately $227 million in cash and short-term investments as of mid-2026. A current ratio above 5.0 and an undrawn $150 million credit line demonstrate excellent liquidity, completely protecting business operations from high interest rates and credit market volatility. While reported financial liabilities include roughly $93 million in long-term building lease obligations for manufacturing cleanrooms, these represent ongoing operational facilities rather than refinancing debt. Management possesses total balance-sheet freedom to self-fund clinical trials and repurchase shares without depending on external capital.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 98.3M | USD 137.5M | USD 1.8M net cash | USD -39.2M | 5.03x |
| 2024 | USD 98.9M | USD 116.2M | USD 24.3M net debt | USD -17.4M | 4.23x |
| 2023 | USD 88M | USD 109.6M | USD 19M net debt | USD -21.5M | 4.49x |
| 2022 | USD 47.6M | USD 119.5M | USD 3.5M net cash | USD -72M | 4.99x |
| 2021 | USD 50.2M | USD 103.4M | USD 18.1M net cash | USD -53.2M | 6.08x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has completed a major multi-year spending cycle after constructing and commissioning its advanced manufacturing plant in Burlington, Massachusetts. Capital spending peaked in 2024 at 27% of revenue during cleanroom construction before falling sharply to under 10% in 2025 and lower in 2026. This deliberate reduction in construction spending has liberated substantial operational liquidity. Because foundational manufacturing capacity is now installed for the next decade, ongoing maintenance investment requires less than 5% of revenue. This shift allowed trailing free cash flow to surge to nearly $50 million, enabling management to direct surplus capital toward an authorized $200 million share repurchase program.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 27.2M | USD 27.6M |
| 2024 | USD 64M | USD 24.8M |
| 2023 | USD 27.5M | USD 21M |
| 2022 | USD 7.6M | USD 19.9M |
| 2021 | USD 7.9M | USD 16.3M |
Behind the synthesisVericel: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The reports exhibit strong independent consensus regarding operational fundamentals: the Burlington facility completion eliminates capital expenditure drag, releasing approximately $50 million in trailing free cash flow, while MACI Arthro expands surgeon adoption. However, reports sharing optimistic assumptions often extrapolate unadjusted EBITDA without adequately deducting stock compensation, facility depreciation, and payer friction. Conversely, the strongest credible contrarian perspective rightly emphasizes that paying 84x trailing earnings in a 5% interest-rate regime creates severe multiple compression risk, even if revenue compounds above 15%. Extreme outlier projections—such as frictionless multiple expansion to $140 or rapid catastrophic obsolescence below $22—lack near-term empirical backing. Weighting therefore favors reports that balance proven cash-flow inflection against rigorous discount-rate discipline, rewarding frameworks that reconcile operating leverage with structural multiple contraction while downweighting unhedged momentum narratives.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 14 opinions
Consensus weight Allocation: 12.0/100. Weight Allocation Rationale: Demonstrating superior analytical rigor, this report reconciles primary SEC filings, verifies lease liabilities versus funded debt, and accounts for equity compensation drag. Its sober 9% annual return expectation properly discounts platform hype, warranting the highest weight.
The 1-year target is $41.0 for , with -24.87% expected return and a SELL ALL rating. The 5-year target is $62.1 for , with +13.67% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 11.0/100. Weight Allocation Rationale: Backed by primary earnings transcript verification, this analysis sharply identifies the duration tax on high multiples and highlights the stock compensation gap in adjusted EBITDA. Its grounded, cash-focused trajectory provides exceptional decision utility.
The 1-year target is $44.9 for , with -17.73% expected return and a SELL ALL rating. The 5-year target is $63.2 for , with +15.67% expected return and a NEUTRAL rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: Grounding its thesis in forensic verification of post-capex cash generation, this report presents a balanced view of operating leverage versus terminal multiple contraction. Its reasonable 26x forward multiple and focus on conversion watchpoints justify an above-average weight.
The 1-year target is $45.5 for , with -16.74% expected return and a SELL ALL rating. The 5-year target is $64.2 for , with +17.58% expected return and a NEUTRAL rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: This analysis excels by focusing on owner earnings, working capital stability, and fortress balance-sheet insulation. Its conservative terminal multiple of 22x and clear-eyed view of sunk Burlington capex provide sound economic reasoning that warrants strong weighting.
The 1-year target is $44.5 for , with -18.48% expected return and a SELL ALL rating. The 5-year target is $69.0 for , with +26.36% expected return and a NEUTRAL rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: This report correctly identifies that heavy non-cash facility depreciation obscures underlying owner cash flows. Its focus on autologous biologic moats and realistic 25x terminal owner-earnings multiples provides credible long-term perspective, supporting a solid weight.
The 1-year target is $43.3 for , with -20.78% expected return and a SELL ALL rating. The 5-year target is $71.2 for , with +30.35% expected return and a NEUTRAL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: This report accurately identifies the thermodynamic bottlenecks of autologous manufacturing and the mathematical inevitability of multiple compression in a high-rate regime. However, it overstates near-term obsolescence from allogeneic competitors, warranting a moderate weight that values its disciplined valuation caution.
The 1-year target is $39.9 for , with -26.93% expected return and a SELL ALL rating. The 5-year target is $44.1 for , with -19.31% expected return and a SELL ALL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: Offering essential contrarian rigor, this report highlights the vulnerability of an 84x trailing multiple against 5% sovereign bond yields and notes insider selling. While somewhat overly punitive regarding top-line durability, its valuation discipline survives scrutiny.
The 1-year target is $39.5 for , with -27.70% expected return and a SELL ALL rating. The 5-year target is $45.3 for , with -17.04% expected return and a SELL ALL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: This report thoroughly examines post-Burlington free cash flow mechanics and institutional NexoBrid integration. However, its baseline assumption of 23% operating margins somewhat downplays specialized biologic selling expenses, warranting a balanced intermediate weight.
The 1-year target is $44.9 for , with -17.73% expected return and a SELL ALL rating. The 5-year target is $75.1 for , with +37.58% expected return and a NEUTRAL rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: Providing excellent analysis of deductible-driven seasonality and cleanroom thermodynamic constraints, this report realistically models earnings growth being partially consumed by multiple compression toward 28x. Its balanced causal framework justifies an above-average weight.
The 1-year target is $42.3 for , with -22.58% expected return and a SELL ALL rating. The 5-year target is $54.2 for , with -0.76% expected return and a PARTIAL SELL rating.
Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: The analysis effectively captures regulatory moats under FDA biologics oversight and sovereign backing via BARDA. However, it underestimates rate-driven multiple compression and models aggressive long-term price targets that rely on flawless execution across international markets.
The 1-year target is $45.7 for , with -16.25% expected return and a SELL ALL rating. The 5-year target is $78.8 for , with +44.19% expected return and a BUY rating.
Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: This perspective provides valuable insight into arthroscopic adoption mechanics and fixed-cost absorption. Nevertheless, its projection of Adjusted EBITDA margins reaching 37% minimizes ongoing cleanroom labor inflation and commercial salesforce overhead, requiring a measured weighting.
The 1-year target is $48.6 for , with -10.96% expected return and a SELL ALL rating. The 5-year target is $95.4 for , with +74.71% expected return and a BUY rating.
Consensus weight Allocation: 5.0/100. Weight Allocation Rationale: The framework effectively links economic machine cycle transitions to cash flow liberation and zero-debt balance sheet resilience. However, its compounded trajectory assumes sustained multiple expansion that conflicts with higher-for-longer cost-of-capital realities.
The 1-year target is $47.9 for , with -12.35% expected return and a SELL ALL rating. The 5-year target is $88.3 for , with +61.59% expected return and a BUY rating.
Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: While thoroughly evaluating the Burlington manufacturing scale and commercial monopoly dynamics, this assessment models extreme multiple resilience and aggressive earnings targets. It severely downweights monetary tightening drag and payer step-therapy frictions, justifying a reduced relative allocation.
The 1-year target is $50.5 for , with -7.56% expected return and a SELL ALL rating. The 5-year target is $107 for , with +95.73% expected return and a STRONG BUY rating.
Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: While identifying commercial inflection drivers and buyback dynamics, this report relies on overly aggressive price trajectory checkpoints that outpace plausible multiple compression constraints. Its optimistic compounding path requires a discounted weighting.
The 1-year target is $50.0 for , with -8.48% expected return and a SELL ALL rating. The 5-year target is $113 for , with +106.90% expected return and a STRONG BUY rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Vericel forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web26 available sources from this batch (61 recorded). The first 15 are shown below; expand to read the rest.
- Package Insert - MACI fda.gov
- Federal Reserve Board - Federal Reserve issues FOMC statement federalreserve.gov
- https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/ex991earningsreleaseq22026.htm?utm_source=openai sec.gov
- Press Release of Vericel Corporation ... sec.gov
- vcel-20251231 sec.gov
- vcel-20260630 sec.gov
- VERICEL CORPORATION - DEF 14A sec.gov
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program - BioSpace biospace.com
- VCEL Stock Quote Price and Forecast | CNN cnn.com
- Vericel Corp (VCEL) Q2 2026 Earnings Call Transcript - Equibles equibles.com
- Vericel Q2 Earnings Call Highlights finance.yahoo.com
- Vericel Q2 2026 slides: 22% revenue growth, first buyback By Investing.com investing.com
- Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility | Vericel Corporation investors.vcel.com
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Vericel Corporation investors.vcel.com
- Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Vericel Corporation investors.vcel.com
Show 11 more sources
- Vericel Reports Second Quarter 2026 Financial Results ... investors.vcel.com
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program | The Manila Times manilatimes.net
- filing public sector pension investment board grows holdings in vericel corporation nasdaqvcel 2025 08 16 marketbeat.com
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance – Ortho Spine News orthospinenews.com
- Vericel (NasdaqGM:VCEL) Stock Forecast & Analyst Predictions - Simply Wall St simplywall.st
- CARTIHEAL AGILI-C Shows Superior 5-Year Knee Pain & Function Results smith-nephew.com
- Vericel Announces FDA Approval and Market Release of MACI Arthro synapse.patsnap.com
- VERICEL CORPORATION - Drug pipelines, Patents, Clinical trials - Synapse synapse.patsnap.com
- Vericel Lifts 2026 Outlook After Standout Quarter - TipRanks.com tipranks.com
- Vericel Corporation Share Price Live Today – NASDAQ:VCEL Stock Price, Chart, News, History upstox.com
- Vericel Corporation | Clinical Development vcel.com
35 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Vericel: forecast questions
What is Vericel (VCEL)'s 1-year price forecast?
Vericel's 1-year target is $44.3 for Sept 2027. The current AI rating is SELL ALL. The expected return from the recorded close is -18.89%, or -18.89% modeled return including net dividends. Latest available market price: USD 54.6, as of 6 Nov 2026. The target date is fixed; this is not a new rolling forecast.
What is Vericel (VCEL)'s 5-year price forecast?
Vericel's 5-year target is $68.1 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +24.68%, or +24.68% modeled return including net dividends. Latest available market price: USD 54.6, as of 6 Nov 2026. The target date is fixed; this is not a new rolling forecast.
How can I compare the AI opinions and audit past Vericel forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Vericel differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Vericel is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.